New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
ApexOnco Front Page
Recent articles
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Chengdu Kanghong's KH815 enters human testing this month.
A biliary tract cancer trial hits on response rate, but survival data will be key.
AACR approaches, along with ASCO abstract titles.
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
